Form 4: Kezar Life Sciences Director Elizabeth Garner Transactions

Elizabeth Garner, a Director at Kezar Life Sciences, Inc., reported transactions related to stock options on May 11, 2026, following a merger.

Summary

• Elizabeth Garner, a Director at Kezar Life Sciences, Inc., filed a Form 4 detailing transactions on May 11, 2026.
• These transactions are related to stock options and occurred in connection with a merger agreement.
• Options with an exercise price equal to or greater than $6.955 per share were cancelled without consideration.
• Options with an exercise price less than $6.955 per share were converted into a cash payment and a Contingent Value Right (CVR) per share.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports on the mechanics of stock option conversion following a merger, with no new financial performance data or strategic shifts.

Positives

• In-the-money stock options were converted into cash and CVRs, providing value to option holders.
• The merger agreement outlines a clear process for handling outstanding stock options.

Negatives

• Out-of-the-money stock options were cancelled and ceased to exist without any consideration.
• The value of the cash and CVRs for in-the-money options is dependent on future events and the terms of the merger.

Risks

• The cancellation of out-of-the-money options represents a loss of potential future gains for those option holders.
• The value of the CVRs is contingent and may not result in additional value for option holders.

Future Outlook

The filing does not contain forward-looking statements or guidance. It reports on past transactions related to a completed merger.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard for reporting insider transactions, particularly in the life sciences sector where equity-based compensation is common and mergers/acquisitions are frequent events.

Stakeholder Impact

• Shareholders: The merger has been completed, and shareholders will be part of the surviving entity or receive consideration as per the merger terms.
• Option Holders: Those holding in-the-money options will receive cash and CVRs. Those holding out-of-the-money options will not receive any consideration for those specific options.

Next Steps

• Shareholders and option holders will receive cash and CVRs for in-the-money options as per the merger agreement.
• Out-of-the-money options have been cancelled.

Key Dates

Keywords

Form 4, Kezar Life Sciences, Elizabeth Garner, stock options, merger, SEC filing, beneficial ownership, CVR